Drug intelligence / Profile preview

NB002

Development stage: Phase 1
Lead developer: NeoLogics Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous Infusion

Overview

NB002 is a multifunctional, Fc-engineered, fully humanized antibody designed to block T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). Developed by Suzhou Neologics Bioscience Co., Ltd., it is being investigated for the treatment of advanced or metastatic solid tumors. TIM-3 is an immune checkpoint receptor that negatively regulates T-cell responses, and by blocking it, NB002 aims to reinvigorate anti-tumor immunity.

Targets

HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)

Beyond the preview

Go deeper on NB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB002.

Explore the full profile